A study to analyze reports to the FAERS of drug-induced IBD occurring in patients receiving biologic therapy for the treatment of rheumatologic diseases

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abatacept (Primary) ; Anakinra (Primary) ; Baricitinib (Primary) ; Belimumab (Primary) ; Canakinumab (Primary) ; Etanercept (Primary) ; Guselkumab (Primary) ; Ixekizumab (Primary) ; Rilonacept (Primary) ; Sarilumab (Primary) ; Secukinumab (Primary) ; Tocilizumab (Primary)
Indications Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriasis; Rheumatic disorders; Rheumatoid arthritis
Focus Adverse reactions

10 Jul 2020 New trial record
19 May 2020 Results published at Gastroenterology in conjunction with the Digestive Disease Week 2020

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com